Sun Y, Tian B, Sheng Z, et al. - Since there exists controversy regarding the difference of effectiveness as well as safety of cinacalcet in the management of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) or end-stage renal disease with other treatments, so, researchers quantitatively evaluated this link via a meta-analysis and systematic review. They analyzed 21 randomized controlled trials that were identified from Embase, PubMed, and Cochrane Library. Significantly reduced serum parathyroid hormone, calcium and calcium phosphorus product concentration were found in patients treated with calcimimetic agents vs control treatment. A significantly higher incidence of nausea, vomiting and hypocalcemia was reported in CKD patients with calcimimetics agents vs control treatment. Overall, treatment of CKD patients with cinacalcet resulted in improvement in the biochemical parameters but failed to improve all-cause mortality and cardiovascular mortality. Moreover, some adverse events can be experienced in relation to treatment with cinacalcet.